Pharmaceuticals(53)

  • Antibody for Preventing/Treating Secondary Respiratory Infections (No. T4-1790)

    A novel method of preventing secondary infections, by inhibition of membrane type I matrix-metalloproteinase-1, which reduces degradation of the extra cellular matrix. ... Read more
    Full Professor Irit Sagi

    Irit Sagi

    Faculty of Biology

    5647
  • Treating Drug-Resistant Lung Cancer Using a Combination of Antibodies (No. T4-1774)

    A novel method to treat tyrosine kinase inhibitor (TKI) resistant cancer by using a combination of three antibodies that target EGFR (ERBB1), HER2 (ERBB2), and HER3 (ERBB3) receptors. ... Read more
    Extension Service Yosef Yarden

    Yosef Yarden

    Faculty of Biology

    5635
  • Treatment of Heart Failure by Inducing Cardiomyocyte Proliferation (No. T4-1752)

    Regulating ErbB2 signaling in cardiomyocytes (CM) as novel treatment for heart diseases by inducing regeneration of cardiac tissue. ... Read more
    Full Professor Eldad Tzahor

    Eldad Tzahor

    Faculty of Biology

    5623
  • rPTE with Potent Organophosphate (OPH) Activities (No. T4-1750)

    Organophosphates are toxic compounds found in chemical warfare agents, such as nerve gases, and insect pesticides.Use of volatile nerve gas agents by terrorist organizations is a key concern of governments around the world. V-type nerve agents (e.g. ... Read more
    Full Professor Dan S. Tawfik

    Dan S. Tawfik

    Biochemistry

    5620
  • Treating Cancer and Collagen-Associated Diseases by Using Anti-LOXL-2 Antibody (No. T4-1743)

    An innovative method for treating diseases associated with dysregulation of collagen fibers in the extracellular matrix (ECM), such as cancer and fibrosis, by targeting LOXL-2. ... Read more
    Full Professor Irit Sagi

    Irit Sagi

    Faculty of Biology

    5611
  • Treatment for Inflammatory Diseases and Cancer (No. T4-1733)

    The development of kinase inhibitors to treat inflammatory diseases was proved beneficial, however, designing specific inhibitors with minimal side effects and prolonged efficacy is challenging as drug resistance often develops. ... Read more
    Full Professor Rony Seger

    Rony Seger

    Faculty of Biology

    5605
  • Preventing Infections Using Lipid Based Molecules (No. T4-1673)

    Sphingosine (SPH), a natural bactericidal agent which acts as a part of the human innate immune system in the skin, was found to be an effective treatment and prophylaxis for bacterial lung infections in cystic fibrosis (CF) mice. ... Read more
    Full Professor Anthony H. Futerman

    Anthony H. Futerman

    Faculty of Biochemistry

    5584
  • MRI of Tissue Fibrosis Without Contrast Agent (No. T4-1665)

    Improved magnetic resonance imaging (MRI) for cardiac fibrosis and other fibrotic diseases.Myocardial fibrosis is associated with worsening ventricular systolic function, abnormal cardiac remodeling, and increased ventricular stiffness, significantly increasing the risk of adverse cardiac outcome ... Read more
    Full Professor Michal Neeman

    Michal Neeman

    Faculty of Biology

    5575
  • Optimizing T Cell Receptor Avidity for Adoptive T Cell Therapies (No. T4-1662)

    Using affinity maturated TCRs to generate reactive T cells ... Read more
    Emeritus Rachel Lea Eisenbach

    Rachel Lea Eisenbach

    Faculty of Biology

    5572
  • Anti-QSOX1 Antibody for Treating Cancer and Metastasis (No. T4-1642)

    Cancer, and especially cancer metastasis, is a leading cause of death worldwide. Research in recent years highlighted the importance of the extracellular matrix (ECM) surrounding the tumor in cancer progression metastasis formation. ... Read more
    Full Professor Deborah Fass

    Deborah Fass

    Faculty of Chemistry

    5560

Pages

Subscribe to Pharmaceuticals